Rapport Therapeutics (RAPP) to Release Earnings on Thursday

Rapport Therapeutics (NASDAQ:RAPP) is expected to release its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Rapport Therapeutics to post earnings of ($0.6241) per share and revenue of $7.50 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Rapport Therapeutics (NASDAQ:RAPP) last announced its earnings results on Tuesday, March 10th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.07). On average, analysts expect Rapport Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Rapport Therapeutics Stock Performance

Shares of RAPP stock traded up $0.06 on Tuesday, hitting $35.59. 163,281 shares of the stock traded hands, compared to its average volume of 336,102. The firm’s 50-day moving average price is $31.60 and its two-hundred day moving average price is $29.10. The stock has a market capitalization of $1.70 billion, a PE ratio of -12.44 and a beta of 0.82. Rapport Therapeutics has a twelve month low of $7.73 and a twelve month high of $42.27.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Wall Street Zen cut shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Citigroup reissued a “market outperform” rating on shares of Rapport Therapeutics in a research report on Tuesday, March 10th. Wells Fargo & Company boosted their price target on shares of Rapport Therapeutics from $43.00 to $46.00 and gave the company an “overweight” rating in a research report on Wednesday, March 11th. Raymond James Financial initiated coverage on shares of Rapport Therapeutics in a research report on Friday, April 10th. They set a “strong-buy” rating and a $66.00 price target on the stock. Finally, BTIG Research reaffirmed a “buy” rating and issued a $53.00 target price on shares of Rapport Therapeutics in a research report on Wednesday, April 22nd. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $54.83.

Insider Buying and Selling

In other Rapport Therapeutics news, insider David Bredt sold 8,500 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $29.02, for a total value of $246,670.00. Following the transaction, the insider owned 387,075 shares of the company’s stock, valued at $11,232,916.50. This represents a 2.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Abraham Ceesay sold 5,833 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $29.34, for a total transaction of $171,140.22. Following the completion of the transaction, the chief executive officer directly owned 556,247 shares in the company, valued at $16,320,286.98. The trade was a 1.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 487,885 shares of company stock valued at $19,319,002 over the last three months. Company insiders own 13.57% of the company’s stock.

Institutional Trading of Rapport Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Meeder Asset Management Inc. purchased a new stake in Rapport Therapeutics during the fourth quarter worth about $37,000. Russell Investments Group Ltd. purchased a new stake in Rapport Therapeutics during the third quarter worth about $43,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Rapport Therapeutics by 86.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company’s stock worth $99,000 after purchasing an additional 4,582 shares during the period. Creative Planning purchased a new stake in Rapport Therapeutics during the second quarter worth about $121,000. Finally, Bank of America Corp DE increased its stake in Rapport Therapeutics by 62.5% during the second quarter. Bank of America Corp DE now owns 12,127 shares of the company’s stock worth $138,000 after purchasing an additional 4,666 shares during the period.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.